Teva Set to Be Hit by EU Fine for Talking Down Rivals
- EU sees evidence firm also delayed competition for MS drug
- Watchdog has concerns over Teva tactics to boost Copaxone
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. is set to be hit with an antitrust fine from the European Union over allegations it tried to talk down rival makers of a multiple sclerosis drug.
The bloc’s executive arm is also prepping the fine over concerns it illegally delayed competition to its multiple sclerosis medicine, Copaxone, according to people familiar with the matter.